Post-Operative Pain Therapeutics Exhibits Emerging Pipeline with 35+ Drug Candidates

Innocoll Holdings plc is using CollaRx technology platform for the development of INL-001 for the treatment of post-operative pain. The CollaRx technology platform produces a lyophilized porous matrix of purified collagen that can be implanted at the time of surgery or applied topically to chronic or acute traumatic wounds.

Access Detailed Report Summary at:  https://www.psmarketresearch.com/market-analysis/post-operative-pain-therapeutics-pipeline-analysis

The CollaRx matrices are biodegradable and bio-resorbable. The in vivo release of drugs incorporated into the CollaRx matrix takes place via a combination of dissolution, diffusion and the interactive characteristics of the active drug and the formulation that can be modified to affect controlled release.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/post-operative-pain-therapeutics-pipeline-analysis/report-sample

Some of the key players developing drugs for post-operative pain include DURECT Corporation, Elite Pharmaceuticals, Inc., Cara Therapeutics, Inc. and others.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=post-operative-pain-therapeutics-pipeline-analysis

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Psoriasis Therapeutic, Clinical Trials, Results, Patent, Designation & Pipeline Analysis

The study analyzed that the psoriasis therapeuticspipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of the skin, causing patches of psoriasis to appear. There are five types of psoriasis namely, plaque psoriasis or psoriasis vulgaris, guttate psoriasis, inverse psoriasis or flexural psoriasis or intertriginous psoriasis, pustular psoriasis, and erythrodermic or exfoliative psoriasis. 

According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by topical route.

Download Free Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/psoriasis-therapeutic-pipeline-analysis/report-sample

MC2 Therapeutics A/S is using PAD technology platform for the development of MC2-01 for the treatment of psoriasis. PAD technology platform offers a number of unique advantages in the development of new topical drugs. PAD vehicles are special made oil-in-water dispersions in which the internal oil phase is stabilized by encapsulation in a thin yet robust aqueous film of surfactants.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=psoriasis-therapeutic-pipeline-analysis

Some of the key players developing drugs for the treatment of psoriasis include Amgen Inc., Maruho Co., Ltd., Boehringer Ingelheim GmbH and others.

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Systemic Lupus Erythematosus Pipeline to Witness Many Collaborations in the Coming Years

The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues.

The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. Some of the common symptoms of systemic lupus erythematosus include oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints.

Download Free Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample

Systemic lupus erythematosus is being treated using a combination approach as number of organs are involved. Therefore, various combination therapies are being used to improve quality of life of the patients. Also, combining novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=systemic-lupus-erythematosus-pipeline-analysis

Seattle Genetics, Inc. is using antibody-drug conjugate (ADC) technology platform for the development of Brentuximab vedotin for the treatment of systemic lupus erythematosus. The technology platform employs a monoclonal antibody specific for a tumor-associated antigen, plus synthetic cytotoxic (cell-killing) agents connected by stable linker systems designed to securely bind the cytotoxic agent to the antibody and then release the agent within the targeted cell.

The research also found that various companies have collaborated for the development of systemic lupus erythematosus pipeline.

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.

Systemic Lupus Erythematosus Pipeline Analysis

·         By Phase

·         By Route of Administration

·         By Target

·         By Company

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Hemophilia Therapeutics Pipeline to Witness Major Collaborations in The Future

The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development. 

The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route.

Download Free Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis/report-sample

Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In September 2016, Roche in collaboration with Chugai Pharmaceutical Co. Ltd. initiated a Phase III trial to evaluate the safety, pharmacokinetics and efficacy of prophylactic subcutaneous emicizumab in patients (aged 12 years) suffering from hemophilia A without factor VIII inhibitors.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hemophilia-therapeutics-pipeline-analysis

Many drug candidates received USFDA designations namely Orphan, Fast Track or Breakthrough designations in their clinical stages for the treatment of hemophilia. In August 2016, Orphan Drug Designation was granted to Phase III drug candidate of Chugai Pharmaceuticals, by Ministry of Health, Labour and Welfare, Japan.

Some of the key players developing drugs for the treatment of hemophilia include Sangamo BioSciences, Inc., Caisson Biotech, Inc., XL-protein GmbH, and others.

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

IgA Nephropathy Pipeline to Witness Various Collaborations in the Coming Years

The study analyzed that the IgAnephropathy pipeline comprises of 12 drug candidates in different stages of development. IgA nephropathy, also known as Berger’s disease, is a kidney disorder that occurs when IgA antibody gets settled in the kidneys. This leads to inflammation that with time hinders the kidney’s ability to filter wastes from blood.

IgA nephropathy is a silent disease in its early stages with no symptoms. But the most common symptoms that are usually observed are proteinuria and hematuria. IgA nephropathy does not have a specific treatment, and the only treatment available is to delay or prevent end stage renal disease (ESRD). Therefore, combination therapies are being used to slow down the rate of proteinuria and hematuria and the use of various targets including a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS) is expected to provide an effective and concrete treatment for the disease, with latest technological advancements further adding to the pipeline growth.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis/report-sample

Pharmalink AB is using TARGIT drug delivery technology platform for the development of Budesonide for IgA nephropathy. The TARGIT technology is based on the application of a combination of enteric polymers onto injection-moulded starch capsules, for the targeted delivery of drugs to specific regions of the large intestine. 

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=iga-nephropathy-pipeline-analysis

The research finds that different companies have collaborated for the development of IgA nephropathy pipeline. In October 2012, Pharmalink AB entered into a contract with Patheon Inc. for manufacturing of Nefecon.

Some of the key players developing drugs for IgA nephropathy include Mallinckrodt plc, Merck KGaA, Anthera Pharmaceuticals, Inc. and others.

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Sjögren’s Syndrome Market Insights in Pathogenic, Clinical Trails and Therapeutic Pipeline Analysis

The study analyzed that Sjögren’s syndromepipeline comprises of approximately 42 drug candidates in different stages of development. Sjögren’s syndrome is a chronic inflammatory disease, which leads to infiltration of lacrimal and salivary glands. It is mostly associated with sicca symptoms, which include dry eyes (xeropthalmia) and dry mouth (xerostomia).

It is also associated with other autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The treatment approaches for this disease mostly include monoclonal antibodies and small molecules, which are being developed to target and reduce the inflammatory mediators. Clinical presentation can vary considerably from relatively mild sicca symptoms, fatigue and arthralgia to severe systemic symptoms such as glomerulonephritis, vasculitis and a host of neurological manifestations.

Download Free Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis/report-sample

The positive results of the drug candidates are speeding up the drug development process for Sjögren’s syndrome. In August 2016, Aldeyra Therapeutics, Inc. presented the positive Phase II results of NS2, a 1% dermatologic cream under Phase II stage of development for Sjögren's syndrome. Six of six (100%) subjects treated with NS2 improved over the course of therapy as assessed by central review, and the improvement was greater than that observed among vehicle-treated patients (p < 0.05).

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=sjogrens-syndrome-therapeutics-pipeline-analysis

The research found that different companies have collaborated for the development of Sjögren’s syndrome.

Some of the key players developing drugs for Sjögren’s syndrome include Kissei Pharmaceutical Co., Ltd., UCB Group, Bristol-Myers Squibb Company and others.

Sjögren’s Syndrome Pipeline Analysis

·         By Phase

·         By Route of Administration

·         By Molecule Type

·         By Company

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Chronic Obstructive Pulmonary Disease Pipeline to Witness Many Technological Advancements in the Coming Years

The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates in different stages of development. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis.

MorphoSys AG is using human combinatorial antibody library (HuCAL) technology platform for the development of their drug candidates in chronic obstructive pulmonary disease. The technology is used for the in vitro generation of highly specific and fully human antibodies.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis/report-sample

The research found that various companies have collaborated for the development of chronic obstructive pulmonary disease therapeutics pipeline. In March 2017, Kyowa Hakko Kirin Co., Ltd. collaborated with AstraZeneca plc, had given the exclusive rights to AstraZeneca plc for benralizumab in Asia.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=copd-therapeutics-pipeline-analysis

Some of the key players developing drugs for the treatment of chronic obstructive pulmonary disease include AstraZeneca plc, GlaxoSmithKline plc, Adamis Pharmaceuticals Corporation and others.

Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Analysis

By Phase

·         By Route of Administration

·         By Molecule Type

·         By Company

Read More

Ulcerative Colitis Therapeutics Pipeline Analysis, 2017 - Clinical Trials, Results, Patent, Designation, Collaboration and Other Developments

The ulcerative colitis pipeline analysis report covers approximately 89 drug candidates in different stages of development.

Ulcerative colitis is a chronic inflammatory disease, which basically affect colonic mucosa. The main identified symptoms of the disease are bloody diarrhea, abdominal cramps and fatigue. Some of the other symptoms include, fever, vomiting, anorexia, abdominal distension and bloating. The treatment approaches to this disease mostly include the use of small molecules and monoclonal antibodies, which are being developed to target and reduce the inflammatory mediators.

Download Free Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis/report-sample

The research found that different companies are engaged in the collaboration for ulcerative colitis. In June, 2015 Lycera Corp. and Celgene Corporation collaborated for the development of Lycera Corp. drug candidate for the treatment of ulcerative colitis. Celgene obtained the exclusive right to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones. During the option period, Lycera retained full control of its research and development programs.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=ulcerative-colitis-pipeline-analysis

Some of the key players developing ulcerative colitis therapeutics include EA Pharma Co., Ltd., Celgene Corporation, InDex Pharmaceuticals AB and others.

Ulcerative Colitis Pipeline Analysis

• By Phase
• By Route of Administration
• By Molecule Type
• By Company

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Clinical Trials & Results, Patent, Designation, Collaboration

The PI3K inhibitors pipeline analysis report covers approximately 37 active drug candidates in different stages of development.

Phosphatidylinositol 3-kinases (PI3K) are lipid kinases that are involved in cell regulation, including cell survival, proliferation and differentiation. They act as intermediate molecules in PI3K/AKT/mTOR signaling pathway by sending chemical messengers from cell surface to cytoplasm. These signals activate multiple effector kinase pathways, resulting in survival and growth of normal cells. Phosphatidylinositol 3-kinases is categorized on the basis of classes as class I, II and III, on the basis of structure of the PI3K, based on the specificities of the substrate as well as on the basis of lipid end-product’s nature. Bases on structure, Phosphatidylinositol 3-kinases has four different forms PI3K alpha, PI3K beta, PI3K gamma and PI3K delta.

Download Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis/report-sample

In March 2017, Bayer AG presented clinical results of Phosphoinositide 3-kinase (PI3K)-targeting drug candidate Copanlisib in Phase II CHRONOS-1 trial, evaluating patients with relapsed or refractory indolent non-Hodgkin's lymphoma (iNHL), trial with NCT ID 01660451. The results across all patient groups showed an objective response rate (ORR) of 59.2%, with a 12% complete response (CR) rate and a median duration of response (DOR) of more than 98 weeks, or 687 days (range 0-687).

  

The research found that different companies engaged in manufacturing of PI3K inhibitors are collaborating. One of the collaborations occurred in November 2016 between Verastem, Inc. and Infinity Pharmaceuticals, Inc.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=phosphoinositide-3-kinase-inhibitor-pipeline-analysis

The major players for PI3K inhibitors pipeline include, but are not limited to, Novartis AG, Genentech, Inc., SignalRX Pharmaceuticals Inc. and others.

PI3K Inhibitors Pipeline Analysis

By Phase

By Route of Administration

By Target

By Company

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More